Showing 500 results

Filters Content type: News, Editors' picks, About HIV Topic: Resistance

Poor adherence and the subsequent development of drug resistance is one reason why HIV treatment can fail. A drug-resistant HIV strain is one which is less susceptible to the effects of one or more anti-HIV drugs.

Treatment simplification strategies

History of drug resistance or virological failure warrants caution when switching to dolutegravir plus lamivudine

News
30 December 2021
Resistance

Antibiotic-resistant strain of gonorrhoea detected in London

Editor's pick
UK Health Security Agency
29 December 2021
Treatment simplification strategies

Implications of historical M184V on use of dual dolutegravir/lamivudine ART

Editor's pick
i-Base
15 November 2021
Resistance

New cases of multi-drug resistant HIV becoming rarer in Europe

News
28 October 2021
Adherence

Dolutegravir-based regimens result in sustained viral suppression, despite lower adherence and treatment interruptions

News
20 August 2021
Resistance

Transmitted Drug Resistance to Tenofovir and Emtricitabine is declining in China

Editor's pick
Infectious Disease Advisor
12 August 2021
PrEP science

PrEP failures in African programmes are rare, but some are happening in people with good adherence

News
21 July 2021
Resistance

Injectable HIV therapy should only be given after a check for innate resistance, French study suggests

News
8 June 2021
Treatment guidelines

Top 5 stories on HIV treatment and care in Africa from CROI 2021

News
23 March 2021
Resistance

Resistance testing does not improve viral suppression after first-line failure in South Africa and Uganda

News
9 March 2021
Sexually transmitted infections prevention

Antibiotics to prevent STIs – for or against?

News
10 February 2021
New & experimental HIV treatments

ViiV Healthcare receives Marketing Authorisation for Rukobia (fostemsavir), a first-in-class attachment inhibitor in combination with other antiretrovirals for the treatment of adults with multidrug-resistant HIV

Editor's pick
ViiV Healthcare press release
8 February 2021
Confidentiality, consent & medical ethics

Molecular HIV surveillance: friend or foe?

News
18 January 2021
Resistance

People with NNRTI resistance have poorer responses to dolutegravir, South African study finds

News
14 December 2020
New & experimental HIV treatments

ViiV Healthcare announces positive CHMP opinion for Rukobia (fostemsavir), a first-in-class attachment inhibitor for the treatment of adults with multidrug-resistant HIV with few treatment options available

Editor's pick
ViiV Healthcare press release
11 December 2020
Resistance

Multidrug Resistance Still Boosts Death Risk in 31,000-Person Italian Study

Editor's pick
NATAP
13 October 2020
New & experimental HIV treatments

Capsid inhibitor lenacapavir, dosed six-monthly, has high barrier to drug resistance and no cross-resistance to other classes

Editor's pick
i-Base
9 October 2020
Treatment interruptions

I’m undetectable: can I take a treatment holiday?

About HIV
September 2020
PrEP science

Two different cases of PrEP failure despite high adherence underline that such events are rare, but should not be ignored

News
4 September 2020
Resistance

Antiretroviral therapy fails to treat one-third of HIV patients in Malawi hospital

Editor's pick
EurekAlert
3 September 2020
Resistance

Darunavir Resistance Development Is Rare in HIV Treatment

Editor's pick
Infectious Disease Advisor
1 September 2020
Resistance

“Unprecedented” case of transmission of four-class resistant HIV virus reported in France

News
11 August 2020
Resistance

Doravirine Benefits HIV-1 Patients with Common Resistance Associated Mutations

Editor's pick
Contagion Live
8 July 2020
HIV treatment for children & young people

Combatting Virologic Failure in Children with HIV using Targeted Drug Resistance Testing

Editor's pick
Contagion Live
8 July 2020